Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/17/2026

Foundational Pharmacologic Management of Chronic Stable Angina

Core Anti‑Ischemic Therapy

  • All adults with chronic stable angina should receive low‑dose aspirin, a beta‑blocker, and a high‑intensity statin as baseline therapy, with sublingual nitroglycerin for immediate symptom relief. [American College of Physicians] 1

Antiplatelet & Antithrombotic Strategy

  • Aspirin 75–325 mg daily reduces cardiovascular events and is recommended for every patient unless a true contraindication exists. [American College of Physicians] 1
  • When aspirin is absolutely contraindicated, clopidogrel 75 mg daily is the preferred alternative antiplatelet agent. [American College of Physicians] 1

Lipid‑Lowering Recommendations

  • Statin therapy should be intensified to achieve an LDL‑cholesterol target < 130 mg/dL, regardless of baseline LDL level. [American College of Physicians] 1
  • In individuals with triglycerides > 200 mg/dL, non‑HDL cholesterol should be lowered to < 130 mg/dL. [American Heart Association] 2

Blood‑Pressure & ACE‑Inhibitor Use

  • Blood‑pressure control to < 130/85 mm Hg is advised, especially in patients with metabolic syndrome. [American Heart Association] 2
  • An ACE inhibitor should be added for all patients, with particularly strong evidence in those who have diabetes, hypertension, heart failure, left‑ventricular dysfunction, or a prior myocardial infarction. [American College of Physicians] 1

Beta‑Blocker Therapy

  • Beta‑blockers are first‑line for angina symptom control and confer a mortality benefit in patients with a prior myocardial infarction. [American College of Physicians] 1

Nitrate Therapy & Tolerance Prevention

  • Sublingual nitroglycerin 0.3–0.6 mg (or isosorbide dinitrate 2.5–10 mg) provides rapid relief of acute angina episodes, typically within 1–7 minutes. [American College of Physicians] 1
  • When long‑acting nitrates are used, a daily nitrate‑free interval of 10–14 hours must be maintained to avoid tolerance. [American College of Physicians] 1

Calcium‑Channel Blocker (CCB) Strategy

  • Long‑acting dihydropyridine CCBs (e.g., amlodipine 5–10 mg daily) are preferred over long‑acting nitrates because they deliver sustained 24‑hour anti‑anginal effect without requiring a drug‑free interval. [American College of Physicians] 1
  • Adding a CCB to a beta‑blocker has the strongest evidence for additive anti‑anginal benefit. [American College of Physicians] 1

Medication Pitfalls to Avoid

  • Short‑acting dihydropyridine CCBs (e.g., immediate‑release nifedipine) should never be given without a concurrent beta‑blocker, as they increase adverse cardiac events. [American College of Physicians] 1
  • Dipyridamole should be avoided because it can worsen exercise‑induced myocardial ischemia. [American College of Physicians] 1
  • Chelation therapy has no proven benefit for chronic stable angina and should not be used. [American College of Physicians] 1
  • Concomitant use of phosphodiesterase‑5 inhibitors (e.g., sildenafil) with nitrates is contraindicated due to the risk of severe hypotension. [American Heart Association] 2

Risk‑Factor Modification

  • Smoking cessation is mandatory for all patients. [American College of Physicians] 1
  • Weight reduction is recommended for patients with obesity (elevated waist circumference). [American Heart Association] 2
  • Glycemic control in diabetes should be achieved with regular fasting‑glucose monitoring. [American College of Physicians; American College of Cardiology] [3][4]
  • Regular physical activity should be encouraged, with symptom monitoring during exertion. [American Heart Association] 2

Follow‑Up Protocol

Visit Frequency

  • Schedule visits every 4–6 months during the first year of therapy, then annually if the patient remains stable. [American College of Physicians; American College of Cardiology] [3][5]

Core Assessment at Each Visit

  • Query changes in physical activity level, angina frequency/severity, medication tolerance, success of risk‑factor modification, and emergence or worsening of comorbid conditions. [American College of Physicians; American College of Cardiology] [3][5]

Physical Examination Focus

  • Measure weight, blood pressure, and pulse; assess jugular venous pressure, carotid arteries, pulmonary fields, and cardiac auscultation for new murmurs or heart‑failure signs. [American College of Cardiology] 5

Cardiac Testing Strategy

  • No routine periodic testing is performed without a change in clinical status. [American College of Physicians] 3
  • Obtain a repeat ECG when initiating or adjusting drugs that affect cardiac conduction, or when the angina pattern changes. [American College of Physicians] 3
  • Order chest radiography for new or worsening heart failure, and echocardiography for suspected new heart failure, myocardial infarction, or valvular disease. [American College of Physicians] 3
  • Perform a treadmill exercise test only in patients with a significant change in clinical status who have not previously undergone revascularization. [American College of Physicians] 3

Alternative Therapies for Refractory Angina (when optimal medical therapy and revascularization are not feasible)

  • Enhanced external counterpulsation (EECP) reduces angina frequency and improves exercise tolerance; 75–80 % of patients report symptom improvement. [American Heart Association; Circulation] [2][6]
  • Spinal cord stimulation may provide analgesic benefit, though long‑term data are limited. [American Heart Association; American College of Physicians; Circulation] [2][3]6
  • Surgical transmyocardial revascularization improves symptoms but has not demonstrated increased myocardial perfusion. [American Heart Association; Circulation] [2][6]

Angina Symptom Management with Medications

First-Line Medications

  • The American College of Cardiology recommends beta-blockers as first-line therapy for angina symptoms, due to their effects on heart rate, contractility, and mortality benefits, and should be titrated to full dose as maintenance therapy for angina symptom control 7, 8
  • Sublingual nitroglycerin or nitroglycerin spray should be provided to all patients with angina for immediate relief of acute symptoms and for prophylactic use before engaging in activities that might trigger angina 9, 8
  • Patients should be warned not to stop beta-blockers suddenly as this can worsen angina; they should be tapered off over four weeks if discontinuation is necessary 10

Second-Line Medications

  • Long-acting calcium channel blockers should be used when beta-blockers are contraindicated or ineffective, as recommended by the European Society of Cardiology 9, 8
  • Long-acting nitrates can be used as an alternative to calcium channel blockers when beta-blockers are contraindicated, but must be administered with a nitrate-free interval to prevent nitrate tolerance 9, 8, 10, 11

Combination Therapy

  • If beta-blocker monotherapy is insufficient, a dihydropyridine calcium channel blocker should be added, as suggested by the European Heart Journal 8
  • Avoid using short-acting dihydropyridine calcium antagonists when not combined with beta-blockers due to increased risk of adverse cardiac events, as warned by the European Society of Cardiology 8, 11

Medications for Prognostic Benefit

  • Aspirin 75-150 mg daily should be prescribed to all patients with coronary artery disease to reduce cardiovascular events, as recommended by the American Heart Association 9, 7
  • Statins should be prescribed for all patients with documented coronary artery disease to reduce adverse ischemic events, as recommended by the American College of Cardiology 9, 7
  • ACE inhibitors should be considered in patients with hypertension, heart failure, left ventricular dysfunction, prior myocardial infarction, or diabetes, as suggested by the European Society of Cardiology 9, 7

Medications to Avoid

  • Dipyridamole is not recommended as it can enhance exercise-induced myocardial ischemia, as stated by the American College of Cardiology 9, 7
  • Chelation therapy is not recommended due to lack of evidence, as reported by the Annals of Internal Medicine 9
  • Short-acting dihydropyridine calcium antagonists should be avoided unless combined with beta-blockers, as warned by the European Society of Cardiology 8, 11

When to Consider Referral for Further Management

  • Patients whose symptoms are not adequately controlled by maximal therapeutic doses of two drugs should be considered for referral for further treatment or investigation, as recommended by the British Medical Journal 10, 12
  • All patients with clinically certain angina should be referred to identify whether they would benefit from prognostic investigation and treatment, as suggested by the British Medical Journal 12

REFERENCES

7

Optimal Management of Suspected or Known Coronary Artery Disease [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

11

Management of Stable Angina [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025